MAGE-A3 and NY-ESO-1 Immunotherapy
Published: Oct 15, 2008 8:00 am
| Brand Name: | |
| Generic Name: | |
| Code Name: | MAGE-A3 and NY-ESO-1 |
| Company: | University of Arkansas |
| FDA Clinical Phase: | 2/3 |
Description:
The purpose of MAGE-A3 and NY-ESO-1 immunotherapy is to generate anti-myeloma T-cells (natural immune system cells) to kill myeloma cells and nothing else.
Clinical Trials:
For a list of clinical trials studying MAGE-A3 and NY-ESO-1 immunotherapy for the treatment of multiple myeloma, see ClinicalTrials.gov.
Source: ClinicalTrials.gov, Multiple Myeloma AND MAGE-A3, http://www.clinicaltrial.gov/ct2/show/NCT00090493?term=multiple+myeloma+AND+MAGE-A3&rank=1 (as of September 4, 2008)
Related Articles:
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
